

Curriculum Vitae

GUIDO A. DAVIDZON, M.D., S.M.
Clinical Associate Professor

Stanford University
Department of Radiology, Nuclear Medicine & Molecular Imaging
300 Pasteur Drive, H2228
Stanford, CA 94305-5105 · (650) 724-4421

II. Educational Background

Medical and Post-Graduate School

02/2008-02/2010 S.M., Master of Science in Biomedical Informatics, Massachusetts Institute of Technology (Cambridge, MA)
03/2000-03/2003 M.D., with Honors, Universidad Maimónides (Buenos Aires, Argentina)

Residency and Fellowship Training

07/02/2012-06/28/2013 Chief resident in Nuclear Medicine & Molecular Imaging, Department of Radiology, Stanford University Medical Center (Stanford, CA)
07/01/2010-06/29/2012 Resident in Nuclear Medicine & Molecular Imaging, Department of Radiology, Stanford University Medical Center (Stanford, CA)
07/2007-06/2010 National Library of Medicine/NIH Fellow in Biomedical Informatics, Harvard University - Massachusetts General Hospital - LCS (Boston, MA)
07/2006-06/2007 Surgical Internship, Department of Surgery, Yale-New Haven Hospital (New Haven, CT)
04/2004-05/2006 Research Fellow, Department of Neurology, Columbia University Medical Center (New York, NY)

III. Professional Appointments

Hospital Appointments

08/16/2016-present Attending Physician, Radiology/NM, Stanford University, CA.
07/2014-08/2016 Nuclear Medicine Physician, Kaiser Permanente, Santa Clara, CA.
10/2015-08/2016 Nuclear Medicine Physician, Kaiser Permanente, San Jose, CA.
07/2013-06/2014 Attending Physician, Radiology/NM, Loyola University, Maywood, IL.
07/2013-06/2014 Nuclear Medicine Physician, Hines VA, Hines, IL.

Academic Appointments

05/2020-present Clinical Associate Professor, Radiology, Stanford University, California
08/2016-04/2020 Clinical Assistant Professor, Radiology, Stanford University, California
11/2015-08/2016 Clinical Assistant Professor, Radiology, Boston University, Boston, MA
11/2013-06/2014 Assistant Professor, Radiology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL
07/2013-11/2013 Instructor Loyola University Chicago, Stritch School of Medicine, Maywood, IL

IV. Honors & Awards

06/2017 First SNMMI Emerging Leaders Award, SMMMI 2017 (Denver, CO)
01/2015 Future Leaders Academy, SNMMI 2015 (San Antonio, TX)
01/2013 Best Abstract Award at the Young Professionals Competition in the 2nd Sino-American Nuclear Medicine Conference SNMMI/ACNM/CSNM 2013 (New Orleans, LA)
01/2012 Best Essay Travel Award, Mid-Winter SNMMI/ACNM 2012 (Orlando, FL)
06/2011 Nuclear Oncology Council Young Investigator Award, SNMMI 2011 (San Antonio, TX)

V. Scholarly Publications

A. Peer-reviewed journal articles (original research)

1. Dimauro S, **Davidzon G**. Mitochondrial DNA and disease. *Ann Med*. 2005;37(3):222-32.
2. Mancuso M, **Davidzon G**, Kurlan RM, Tawil R, Bonilla E, Di Mauro S, Powers JM. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. *J Neuropathol Exp Neurol*. 2005;64(4):280-94.
3. **Davidzon G**, Mancuso M, Ferraris S, Quinzii C, Hirano M, Peters HL, Kirby D, Thorburn DR, DiMauro S. POLG mutations and Alpers syndrome. *Ann Neurol*. 2005;57(6):921-3.
4. **Davidzon G**, Greene P, Mancuso M, Klos KJ, Ahlskog JE, Hirano M, DiMauro S. Early-onset familial parkinsonism due to POLG mutations. *Ann Neurol*. 2006;59(5):859-62.
5. DiMauro S, **Davidzon G**, Hirano M. A polymorphic polymerase. *Brain*. 2006;129(Pt 7):1637-9.
6. Oskoui M, **Davidzon G**, Pascual J, Erazo R, Gurgel-Giannetti J, Krishna S, Bonilla E, De Vivo DC, Shanske S, DiMauro S. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. *Arch Neurol*. 2006;63(8):1122-6.
7. Scuderi C, Borgione E, Musumeci S, Elia M, Castello F, Fichera M, **Davidzon G**, DiMauro S. Severe encephalomyopathy in a patient with homoplasmic A5814G point mutation in mitochondrial tRNACys gene. *Neuromuscul Disord*. 2007;17(3):258-61.
8. Hakonen AH, **Davidzon G**, Salemi R, Bindoff LA, Van Goethem G, Dimauro S, Thorburn DR, Suomalainen A. Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. *Eur J Hum Genet*. 2007;15(7):779-83.
9. Wiltshire E, **Davidzon G**, DiMauro S, Akman HO, Sadleir L, Haas L, Zuccollo J, McEwen A, Thorburn DR. Juvenile Alpers disease. *Arch Neurol*. 2008;65(1):121-4.
10. Ferraris S, Clark S, Garelli E, **Davidzon G**, Moore SA, Kardon RH, Bienstock RJ, Longley MJ, Mancuso M, Gutierrez Rios P, Hirano M, Copeland WC, DiMauro S. Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1. *Arch Neurol*. 2008;65(1):125-31.
11. Mancuso M, Ricci G, Choub A, Filosto M, DiMauro S, **Davidzon G**, Tessa A, Santorelli FM, Murri L, Siciliano G. Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: report of a family. *J Affect Disord*. 2008;106(1-2):173-7.
12. Rohrbach M, Chitayat D, Maegawa G, Shanske S, **Davidzon G**, Chong K, Clarke JT, Toi A, Tarnopolsky M, Robinson B, Blaser S. Intracerebral periventricular pseudocysts in a fetus with mitochondrial depletion syndrome: an association or coincidence. *Fetal Diagn Ther*. 2009;25(2):177-82
13. Marcus, A.; **Davidzon, G.**; Law, D.; Verma, N.; Fletcher, R.; Khan, A.; Sarmenta, L. Using NFC-Enabled Mobile Phones for Public Health in Developing Countries. *IEEE. Near Field Communication, 2009. NFC '09. First International Workshop on*. Page(s): 30-35.
14. Akman HO, **Davidzon G**, Tanji K, Macdermott EJ, Larsen L, Davidson MM, Haller RG, Szczepaniak LS, Lehman TJ, Hirano M, DiMauro S. Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. *Neuromuscul Disord*. 2010 Jun;20(6):397-402.
15. Leo Anthony G. Celi, MD, MS, MPH, Robin J. Tang, MBA, Mauricio C. Villarroel, **Guido A. Davidzon, MD, MS**, William T. Lester, MD, Henry C. Chueh, MD, MS. A Clinical Database-Driven Approach to Decision Support: Predicting Mortality Among Patients with Acute Kidney Injury. *Journal of Healthcare Engineering*. Volume 2, Number 1 / March 2011, pages: 97-110
16. Viswam S. Nair, Olivier Gevaert, **Guido Davidzon**, Sandy Napel, Edward E. Graves, Chuong D. Hoang, Joseph B. Shrager, Andrew Quon, Daniel L. Rubin, Sylvia K. Plevritis. Prognostic PET ¹⁸F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. *Cancer Research*. 2012 Aug 1;72(15):3725-34. Epub 2012 Jun 18.
17. Celi L.A., Galvin S., **Davidzon G.**, Lee J., Scott D., Mark R. A Database-driven Decision Support System: Customized Mortality Prediction. *Journal of Personalized Medicine*. 2012; 2(4):138-148.
18. Nair VS, Gevaert O, **Davidzon G**, Plevritis SK, West R. NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism. *Lung Cancer*. 2014 Feb;83(2):189-96
19. Erik Mitra, **Guido Davidzon**. Diagnosis Please: Hodgkin lymphoma with paraneoplastic hypercalcemic pancreatitis. *Radiology* July 2014;272(1):296-300.

20. Celi LA, **Davidzon G**, Johnson AE, Komorowski M, Marshall DC, Nair SS, Phillips CT, Pollard TJ, Raffa JD, Saliccioli JD, Salgueiro FM, Stone DJ. Bridging the Health Data Divide. *J Med Internet Res*. 2016 Dec 20;18(12):e325.
21. Baratto L, Park SY, Hatami N, **Davidzon G**, Srinivas S, Gambhir SS, Iagaru A. 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT. *PLoS One*. 2017 Jun 5;12(6).
22. Lucia Baratto*, **Guido A. Davidzon***, Mateen Moghbel, Negin Hatami, Andrei Iagaru, Erik S. Mittra. Comparison between different PET and CT-based imaging interpretation criteria at interim in patients with diffuse large B cell lymphoma. *Clin Nucl Med*. 2018 Jan;43(1):1-8
23. Sonya Youngju Park; Lucia Barrato; Negin Hatami; **Guido Davidzon**; Shyam Srinivas; Sanjiv Sam Gambhir; Andrei Iagaru. Initial Experience with a New PET/CT System Using SiPM Detectors. *EJNMMI Phys*. 2018 Apr 18;5(1):9.
24. Sarah M Mattonen, **Guido A Davidzon**, S Bakr, S Echeharay, A Leung, M Vasanaawala, G Horng, S Napel, V Nair. 18F FDG Positron Emission Tomography (PET) Tumor Penumbra Imaging Features Predict Outcome in Non-Small Cell Lung Cancer. *AJRCCM* 2018;197:A7420
25. Mattonen, S. A., **Davidzon, G. A.**, Bakr, S., Echeharay, S., Leung, A. N., Vasanaawala, M., Horng, G., Napel, S., Nair, V. S. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer. *Tomography*. 2019; 5 (1): 145–53.
26. Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, **Davidzon G**, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from ⁶⁸Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2019 Jul 27. doi: 10.1007/s00259-019-04455-9.
27. Laudicella R., **Davidzon G.**, Vasanaawala S., Baldari S., Iagaru A. 18F-FDG PET/MR refines evaluation in newly diagnosed metastatic urethral adenocarcinoma. *Nuclear Medicine and Molecular Imaging August 2019, Volume 53, Issue 4, pp 296–299.*
28. Toriihara A, Nobashi T, Baratto T, Duan H, Moradi F, Park S, Hatami N, Aparici C, **Davidzon G**, Iagaru A. Comparison of three interpretation criteria of ⁶⁸Ga-PSMA11 PET based on inter -and intra-reader agreement. *J Nucl Med*. 2019 Sep 27.
29. Song H, Harrison C, Duan H, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, **Davidzon G**, Iagaru A. Prospective Evaluation in an Academic Center of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: *J Nucl Med*. 2019 Oct 18.
30. Nobashi T, Zacharias C, Ellis JK, Ferri V, Koran ME, Franc BL, Iagaru A, **Davidzon GA**. Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain ¹⁸F-FDG-PET Scans. *J Digit Imaging*. 2020. Apr;33(2):447-455.
31. Mattonen SA, **Davidzon GA**, Benson J, Leung ANC, Vasanaawala M, Horng G, Shrager JB, Napel S, Nair VS. Bone Marrow and Tumor Radiomics at ¹⁸F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer. *Radiology*. 2019 Nov;293(2):451:459
32. Park SY, Barrato L, Hatami N, **Davidzon G**, Gambhir SS, Iagaru A. Iniatial Experience with a PET/computed tomography system using silicon photomultiplier detectors. *Nucl Med Commun*. 2019 Nov;40(11): 1174-1178.
33. Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, **Davidzon GA**, Iagaru A. Prospective Evaluation of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. *J Nucl Med*. 2020 Apr;61(4):546-551. doi: 10.2967/jnumed.119.231654. Epub 2019 Oct 18. PMID: 31628216.
34. Guja KE, Brown R, Girod B, Song H, Harrison C, Franc BL, Moradi F, **Davidzon G**, Iagaru A, Aparici CM. An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [¹⁸F]FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2020 Sep 12. doi: 10.1007/s00259-020-05026-z. Epub ahead of print. PMID: 32918110.
35. Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, **Davidzon G**, Aparici CM, Nguyen J, Moradi F, Iagaru A, Franc BL. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. *Eur J Nucl Med Mol Imaging*. 2020 Apr 15. doi: 10.1007/s00259-020-04792-0. Epub ahead of print. PMID: 32296882.
36. Mormino EC, Toueg TN, Azevedo C, Castillo JB, Guo W, Nadiadwala A, Corso NK, Hall JN, Fan A, Trelle AN, Harrison MB, Hunt MP, Sha SJ, Deutsch G, James M, Fredericks CA, Koran ME, Zeineh M, Poston K, Greicius MD, Khalighi M, **Davidzon GA**, Shen B, Zaharchuk G, Wagner AD, Chin FT. Tau PET imaging with ¹⁸F-PI-2620 in aging and neurodegenerative diseases. *Eur J Nucl Med Mol Imaging*. 2020 Jun 23. doi: 10.1007/s00259-020-04923-7. Epub ahead of print. PMID: 32572562.
37. Reith F, Koran ME, **Davidzon G**, Zaharchuk G; Alzheimer's Disease Neuroimaging Initiative. Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on ¹⁸F-Florbetapir PET Using ADNI Data. *AJNR Am J Neuroradiol*. 2020 Jun;41(6):980-986. doi: 10.3174/ajnr.A6573. Epub 2020 Jun 4. PMID: 32499247; PMCID: PMC7342760.

38. Lee JJ, Yang H, Franc BL, Iagaru A, **Davidzon GA**. Deep learning detection of prostate cancer recurrence with ¹⁸F-FACBC (fluciclovine, Axumin®) positron emission tomography. *Eur J Nucl Med Mol Imaging*. 2020 Jun 17. doi: 10.1007/s00259-020-04912-w. Epub ahead of print. PMID: 32556481.
39. Chen KT, Schürer M, Ouyang J, Koran MEI, **Davidzon G**, Mormino E, Tiepolt S, Hoffmann KT, Sabri O, Zaharchuk G, Barthel H. Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. *Eur J Nucl Med Mol Imaging*. 2020 Jun 13. doi: 10.1007/s00259-020-04897-6. Epub ahead of print. PMID: 32535655.
40. Beinat C, Patel CB, Haywood T, Shen B, Naya L, Gandhi H, Holley D, Khalighi M, Iagaru A, **Davidzon G**, Gambhir SS. Human biodistribution and radiation dosimetry of [¹⁸F]DASA-23, a PET probe targeting pyruvate kinase M2. *Eur J Nucl Med Mol Imaging*. 2020 Aug;47(9):2123-2130. doi: 10.1007/s00259-020-04687-0. Epub 2020 Jan 15. PMID: 31938892.
41. Nakamoto R, C Zaba L, Rosenberg J, Arani Reddy S, W Nobashi T, Ferri V, **Davidzon G**, Mari Aparici C, Nguyen J, Moradi F, Iagaru A, Lewis Franc B. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[¹⁸F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. *Mol Imaging Biol*. 2021. Feb;23(1):139-147.
42. Guja KE, Brown R, Girod B, Song H, Harrison C, Franc BL, Moradi F, **Davidzon G**, Iagaru A, Aparici CM. An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [¹⁸F]FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2021 Apr;48(4):1256-1257.
43. Trelle AN, Carr VA, Wilson EN, Swarovski MS, Hunt MP, Toueg TN, Tran TT, Channappa D, Corso NK, Thieu MK, Jayakumar M, Nadiadwala A, Guo W, Tanner NJ, Bernstein JD, Litovsky CP, Guerin SA, Khazenzon AM, Harrison MB, Rutt BK, Deutsch GK, Chin FT, **Davidzon GA**, Hall JN, Sha SJ, Fredericks CA, Andreasson KI, Kerchner GA, Wagner AD, Mormino EC. Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. *Neurology*. 2021 Mar 9;96(10):e1470-e1481.
44. Chen KT, Toueg TN, Koran MEI, **Davidzon G**, Zeineh M, Holley D, Gandhi H, Halbert K, Boumis A, Kennedy G, Mormino E, Khalighi M, Zaharchuk G. True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation. *Eur J Nucl Med Mol Imaging*. 2021 Jan 8.
45. Nakamoto R, Harrison C, Song H, Guja KE, Hatami N, Nguyen J, Moradi F, Franc BL, Aparici CM, **Davidzon G**, Iagaru A. The Clinical Utility of ¹⁸F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval. *Mol Imaging Biol*. 2021 Jan 19.
46. Zaharchuk G, **Davidzon G**. Artificial Intelligence for Optimization and Interpretation of PET/CT and PET/MR Images. *Semin Nucl Med*. 2021 Mar;51(2):134-142.
47. Nakamoto R, Zaba LC, Liang T, Reddy SA, **Davidzon G**, Aparici CM, Nguyen J, Moradi F, Iagaru A, Franc BL. Prognostic value of bone marrow metabolism on pretreatment ¹⁸F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. *J Nucl Med*. 2021 Feb 5.
48. Baratto L, Song H, Duan H, Hatami N, Bagshaw H, Buyyounouski M, Hancock S, Shah SA, Srinivas S, Swift P, Moradi F, **Davidzon GA**, Iagaru A. PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. *J Nucl Med*. 2021 Mar 5.
49. Eyuboglu S, Angus G, Patel BN, Pareek A, **Davidzon G**, Long J, Dunnmon J, Lungren MP. Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT. *Nat Commun*. 2021 Mar 25;12(1):1880
50. Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, **Davidzon GA**, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. *Mol Imaging Biol*. 2021 Apr 26:1–14.

B. Peer-reviewed publications other

1. Bradley KM, McGowan DR, Gleeson FV, Johnson GB, Young JR, Levin CS, **Davidzon GA**, Iagaru AH. Embrace Progress. *J Nucl Med*. 2018 Jul;59(7):1169.

D. Books Chapters

1. Progressing to PET/MR Imaging: FDG-PET/CT Initial and Subsequent Therapy Evaluation; Camila Mosci, **Guido A Davidzon** and Andrew Quon. *PET Clinics Vol 7 Number 4*, p. 369-380. October 2012, PET Imaging of the Head and Neck, Yao and Faulhaber. ELSEVIER.

2. Celi Leo A.; Tang RJ; Villarroel MC; **Davidzon G**; Lester WT; Chueh HC. In: Chyu, Ming-Chien, editor. *Advances in critical care engineering*. Essex: Multi-Science Publishing Co., Ltd.; 2011. p. 171-83.

H. Abstracts Not Published in other Forms

1. **Davidzon GA**, Pankey E, Loudon T, Schmid P, Berger B, Berkowicz DA. SemanticDx: A Prototype to Facilitate Use of Biostatistics at the Point-of-care. *AMIA Annu Symp Proc*. 2008: p. 921.
2. **Davidzon G.**, Celi Leo, Mauricio Villarroel, William Lester. Improving Mortality Prediction Among Patients with Subarachnoid Hemorrhage. *AMIA Annu Symp Proc*. 2009.
3. **Davidzon Guido**, Blesius Carl, Celi Leo, William Lester. Using EMR Transactional Data for Personalized Decision Support. *AMA-IEEE Medical Technology Conference on Individualized Healthcare*. March 2010.
4. **Guido Davidzon**, Erik Mittra. Comparison of Five Different Imaging Response Criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT. *SNMMI 2011 Annual Meeting*.
5. **Davidzon GA**, Nair VS, Mittra E, Graves E, Loo BW, Rubin DR. Novel pre-operative ¹⁸F-FDG PET imaging features augment outcome prediction post-operatively in patients with resected NSCLC. *WRSNMMI 2011 Annual Meeting*.
6. **Davidzon Guido**, Heather Wakelee, Joel Neal, Erik Mittra, Andrew Quon, Andrei Iagaru. Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. *SNMMI 2012 Annual Meeting*.
7. **Davidzon Guido**, Zhigang Peng, Anand Vikram, Zhou Sean, Andrew Quon. Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis. *SNMMI 2012 Annual Meeting*.
8. **Davidzon G**, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS, Iagaru A, Biodistribution and Kinetics of 18F FPPRGD2 PET/CT in the Evaluation of Suspected Recurrence in Glioblastoma Multiforme. *Mid-Winter SNMMI/ACNM 2012*.
9. Lucia Baratto, Akira Toriihara, Negin Hatami, **Guido A. Davidzon**, Shyam Srinivas, Sanjiv S. Gambhir, Andrei Iagaru. SiPM-Based versus LYSO-based 68Ga-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. *RSNA 2018*.
10. Baratto, L.; Duan, H.; Harrison, C.; Mari, C.; **Davidzon, G.**; Yohannan, T.; Iagaru, A. Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. *EANM 2018*.
11. Baratto, L.; Duan, H.; Minamimoto, R.; Mari, C.; Yohannan, T.; **Davidzon, G.**; Iagaru, A. Ga-68-RM2 PET vs. Ga-68-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer. *EANM 2018*
12. Duan, H.; Park, S.; Baratto, L.; Hatami, N.; Khalaf, M. H.; Yohannan, T. K.; **Davidzon, G. A.**; Iagaru, A. H. Ga-68-PSMA-11 Imaging for Biochemical Relapse of Prostate Cancer Using Dual-Time LYSO and SiPM-Based Detectors PET/CT. *RSNA 2018*.
13. Baratto, L; Duan, H.; Hatami, N.; Yohannan, T.; Mari, C.; **Davidzon, G.**; Iagaru, A. Dual-Time Ga-68-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT. *EANM 2018*.
14. Dimitrios Colevas, Nikita Bedi, Serena Chang, Uriel Yojanan Moreno Nieves, Susmita Chatterjee, **Guido Alejandro Davidzon**, Shyam Srinivas, Quynh-Thu Le, Aruna Gambhir, John B. Sunwoo. A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with ¹⁸F -AraG. *Journal of Clinical Oncology 2018 36:15_suppl, 6050-6050*.
15. T Nobashi, C Zacharias, A Iagaru, **G Davidzon**, Detection of Abnormal Brain FDG-PET Images with Deep Learning. *RSNA 2018*.
16. Hong Song, Pamela Kunz, Thomas Yohannan, Erik S. Mittra, Andrei Iagaru, **Guido A. Davidzon**. 68Ga-DOTATATE PET/CT as a Predictive Marker for ¹⁷⁷Lu-DOTATATE Therapy. *RSNA 2018*.
17. **Guido A. Davidzon**, JJ. Lee, H. Yang, H. Song, C. Harrison, A. Iagaru. Machine Learning to Detect Prostate Cancer Recurrence Using ¹⁸F-fluciclovine PET. Rapid Fire session at EANM 2019. Springer. 2019: S65–S66
18. Fan, A. P., Chen, K. T., Nadiadwala, A., Toueg, T., Sha, S., Greicius, M. D., **Davidzon, G. A.**, Chin, F. T., Zaharchuk, G., Mormino, E. C. Non-invasive quantification of tau accumulation in dementia using simultaneous F-18-PI-2620 PET/MRI. Sage Publications Inc. 2019: 110–11.
19. Iagaru, A., Duan, H., Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., **Davidzon, G**. Prospective evaluation of F-18-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. Springer. 2019: S593
20. Iagaru, A., Baratto, L., Duan, H., Hatami, N., Mari, C., **Davidzon, G**. Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. Springer. 2019: S277–S278.

VI. Editorial Service

Peer review activities

2013-present Review manuscripts for Molecular Pharmaceutics, BMC Cancer, RSNA, Plos ONE, EJNMMI Research.

VI. Grants

A. Current Funding

5/1/2019-4/30/2022 NIH: Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome (PI)
11/13/2019-11/01/2020 General Electric: PART TWO Deep Learning in Whole Body FDG-PET CT Characterization for Clinical Decision Support (Co-PI)
1/15/2019-01/1/2022 DimensionalMechanics: Radiologist-Level Classification of Scintigraphy and PET/CT Images Using Deep Neural Networks. (PI)
6/05/2019- 5/31/2023 Genentech, Inc: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of MTAU9937A in patients with moderate Alzheimer's Disease (COI)
9/20/2019- 8/31/2024 NIH: The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease (COI)
11/01/2019-12/21/2020 Kheiron Medical Technologies: The Kaplan Project Foundational Phase with Kheiron Medical Technologies (PI)
04/01/2020-02/28/2025 NIH: Effects of attention and goal-state lapses on memory in healthy and pathological aging (COI)
09/05/2019-09/04/2021 AAA: Ga68 NEOBomb-1 and Ga68 PSMA R2 PET/MRI in Biochemically Recurrent Prostate Cancer (COI)
03/02/2020-03/31/2020 Eisai, Inc: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease (COI)
08/01/2019-07/31/2024 NIH: Evaluation of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI (COI)

X. University Administrative Service

A. Committee service

2017-present Committee Member, Radiology Faculty Diversity Committee, Stanford University
2017-present Member, Clinical Radiation Safety Committee (CRSCO), Stanford University
2014-2016 Innovation Consultant, Nuclear Medicine Department, Kaiser Permanente

B. Leadership roles

10/17/2016-present Director, DXA Imaging Program, Stanford Health Care, CA.
01/01/2018-present Lead Artificial Intelligence in Nuclear Medicine, Stanford University
01/01/2019-present Lead NM Quantitative Cardiac PET imaging, Stanford Health Care, CA.
1/2017-12/2018 Interim Lead, Targeted Radionuclide Therapy Program, Stanford Health Care, CA.

C. Mentorship

Current Mentees: Hong Song, M.D., Ph.D, Eduardo Somoza, M.D.

Past Mentees: Tomomi Nobashi, M.D., Ph.D, JongJin Lee, M.D. Ph.D

XI. Service to Professional Organizations

A. Membership

2017-present European Association of Nuclear Medicine (EANM)
2013-present Radiology Society of North America (RSNA)
2010-present American Roentgen Ray Society (ARRS), Member
2010-present American College of Nuclear Medicine (ACNM), Member
2010-present Society of Nuclear Medicine and Molecular Imaging (SNMMI), Member
2007-2018 American Medical Informatics Association (AMIA), Member

D. Committee service

2017-2020 Committee Member, Prostate Cancer Outreach Working Group (SNMMI)
2020-present Member, Diversity, Equity and Inclusion Task Force (SNMMI)

E. Leadership roles

2016-2017 Secretary/Treasurer, SNMMI Northern California
2017 Chair, 4th Sino-American Nuclear Medicine Conference - Mid-Winter SNMMI, Phoenix, AZ
2017-2018 Scientific Program Chair, 2018 NCSNMMI Annual Chapter Meeting
2018-2019 General Program Chair, 2019 NCSNMMI Annual Chapter Meeting
Vice President, SNMMI Northern California Chapter
2020-Current President-elect, SNMMI Northern California Chapter

XII. Other Services

A. Moderator

09/2020 Global Health Research, Diversity in Radiology and Molecular Imaging 2020 WMIS (Stanford, CA)
02/2020 MIBG Oncologic Imaging, NCSNMMI 2020 (Pleasanton, CA)

XIII. Presentations

F. National and Regional Meetings

02/2021 “Artificial Intelligence in Nuclear Medicine & Molecular Imaging”, NCSNMMI 2021 (Virtual, CA)
02/2020 “PET Brain Evaluation of Cognitive Impairment”, NCSNMMI 2020 (Pleasanton, CA)
11/19 “Amyloid PET Brain Imaging”, WRSNMMI 2019 (Tucson, AZ)
11/17 “Peptide Receptor Radionuclide Therapy”, NET 2017, Stanford *CME* (Stanford, CA)
02/17 “Cardiac Imaging: Past, Present and Future”, NCSNMMI 2017 (Pleasanton, CA)
04/14 “PET/CT: Imaging Response Criteria”, Pekin Union Medical College (Beijing, China)
01/13, 6/13 “PET: Absolute Quantification of Myocardial Blood Flow”, Michael E. De Bakey VAMC (Houston, TX), at Stanford Radiology and Cardiology Department lectures.
01/13 “Biodistribution and kinetics of 18F FPPRGD2 PET/CT in the evaluation of suspected recurrence in glioblastoma multiforme”, Mid-Winter SNMMI/ACNM 2013 (New Orleans, LA)
01/12 “Comparison of five different imaging response criteria in patients with Diffuse Large B-Cell lymphoma using FDG-PET/CT” Mid-Winter SNMMI/ACNM 2012 (Orlando, FL)
06/11 “Lymphoma and the Utility of PET/CT for Response Assessment”, Nuclear Medicine Grand Rounds, Stanford University Medical Center
06/11 “Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT” SNMMI 2011 (San Antonio, TX)
03/10 “Using EMR Transactional Data for Personalized Decision Support”. AMA-IEEE Medical Technology Conference on Individualized Healthcare. (Washington, D.C.)

- 03/09, 5/09, 11/09 “Improving Mortality Prediction Among Patients with Subarachnoid Hemorrhage.” Presented at MGH, Lab for Computational Physiology at MIT, DSG at Brigham and Women’s Hospital (Boston, MA), at AMIA 2009 Annual Symposium (San Francisco, CA).
- 03/09 “Using NFC-Enabled Mobile Phones for Public Health in Developing Countries.” AMIA 2009 Spring Conference. (Orlando, FL)
- 11/08 “SemanticDx: A Prototype to Facilitate Use of Biostatistics at the Point-of-care.” AMIA 2008 Annual Symposium. (Washington, D.C.)
- 03/06, 04/06 “Early-Onset Familial Parkinsonism Due to *POLG* Mutations.” Neurology Department Grand Rounds, CUMC and AAN.

G. International

- 02/21 “Artificial Intelligence in Nuclear Medicine” EBM of Cancers, Tata Memorial Centre (Mumbai, India)
- 06/19 Role of AI in Molecular Imaging Panel, GE: PET/CT Meet the Experts, University of Bologna (Bologna, Italy)
- 09/18 “Artificial Intelligence and Medical Imaging”, Datathon – Workshop, Khon Kaen University, Thailand
- 05/18 “Artificial Intelligence and Medical Imaging”, JIGTMII / JISA (Tucuman and Buenos Aires, Argentina)
- 10/17 “Clinical Comparison of Digital SiPM PET/CT and Standard PET/CT Scanners”, AOCNMB 2017 (Yokohama, Japan)
- 04/14 “PET: Absolute Quantification of Myocardial Blood Flow”, Pekin Union Medical College. (Beijing, China)

H. Current Lectures

- 2016-2021 **Radiology 301A Clerkship**
School of Medicine, Stanford University, CA
- Introduction to Nuclear Medicine
 - Nuclear Medicine Therapies
 - Introduction to PET/CT
- Radiology Core Lecture Series**
Dept. of Radiology, Stanford Hospital, CA
- AI in NM & Molecular Imaging
 - PET/CT: Lymphoma
 - PET/CT: in CI and Dementia
 - PET/CT: Myocardial Perfusion and Flow Quantification
 - PET/CT: Sarcoid and Viability
 - Theranostics: PRRT
 - NM: What do you need to know for most common on-call studies?
 - NM Board Review Cases
- Controversies in the Management of Thyroid Cancer
 - Evaluation of Renal Function
 - DXA Imaging
 - End-of-Year NM Test
- BioEngineering 224/Radiology 224**
Molecular Imaging Program at Stanford
- Clinical NM: Past, Present and Future
 - Artificial Intelligence in Nuclear Medicine
- Cardiology Fellowship Lecture Series**
- Non-Invasive Evaluation of Myocardial Perfusion